Knowledge Hub

20s Proteasome - Pipeline Review, H2 2016

Press release   •   Nov 28, 2016 05:24 EST has recently announced the addition of a market study “ 20s Proteasome - Pipeline Review, H2 2016”, is a comparative analysis of the global market.

20s Proteasome - Pipeline Review, H2 2016


Global Markets Directs, 20s Proteasome - Pipeline Review, H2 2016, provides in depth analysis on 20s Proteasome targeted pipeline therapeutics.

The report provides comprehensive information on the 20s Proteasome , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 20s Proteasome targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Download The sample Copy Of This Report:


- The report provides a snapshot of the global therapeutic landscape for 20s Proteasome

- The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects

- The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to 20s Proteasome targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for 20s Proteasome

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Content

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

20s Proteasome Overview 6

Therapeutics Development 7

20s Proteasome - Products under Development by Stage of Development 7

20s Proteasome - Products under Development by Therapy Area 8

20s Proteasome - Products under Development by Indication 9

20s Proteasome - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

20s Proteasome - Products under Development by Companies 13

20s Proteasome - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

20s Proteasome - Companies Involved in Therapeutics Development 21

Amgen Inc. 21

LG Life Science LTD. 23

Triphase Accelerator Corporation 24

20s Proteasome - Drug Profiles 25

carfilzomib - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

marizomib - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

oprozomib - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

VPE-001 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

VPEA-002 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

VPEA-004 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

VR-23 - Drug Profile 48